What happens with schizophrenia patients after their discharge from hospital? Results on outcome and treatment from a “real-world” 2-year follow-up trial

被引:0
|
作者
Rebecca Schennach
Michael Riedel
Michael Obermeier
Markus Jäger
Max Schmauss
Gerd Laux
Herbert Pfeiffer
Dieter Naber
Lutz G. Schmidt
Wolfgang Gaebel
Joachim Klosterkötter
Isabella Heuser
Wolfgang Maier
Matthias R. Lemke
Eckart Rüther
Stefan Klingberg
Markus Gastpar
Florian Seemüller
Ilja Spellmann
Richard Musil
Hans-Jürgen Möller
机构
[1] Ludwig-Maximilians-University,Department of Psychiatry and Psychotherapy
[2] Schoen Clinic Roseneck,Psychiatric Clinic
[3] District Hospital Augsburg,Psychiatric Clinic
[4] Inn-Salzach Hospital,Psychiatric Clinic
[5] Isar-Amper Hospital,Department of Psychiatry and Psychotherapy
[6] University of Hamburg,Department of Psychiatry and Psychotherapy
[7] University of Mainz,Department of Psychiatry and Psychotherapy, Medical Faculty
[8] Heinrich-Heine-University Duesseldorf,Department of Psychiatry and Psychotherapy
[9] University of Cologne,Department of Psychiatry and Psychotherapy
[10] Charite Berlin,Department of Psychiatry and Psychotherapy
[11] University of Bonn,Department of Psychiatry
[12] Alsterdorf Hospital,Department of Psychiatry and Psychotherapy
[13] University of Göttingen,Department of Psychiatry and Psychotherapy
[14] University of Tübingen,Department of Psychiatry and Psychotherapy
[15] University of Essen,Psychiatric Clinic
[16] Sächsisches Krankenhaus Rodewisch,Department of Psychiatry and Psychotherapy
[17] Bezirkskrankenhaus Kempten,Department of Special Psychiatry, Social Psychiatry and Psychotherapy
[18] Klinikum Stuttgart,undefined
关键词
Schizophrenia; Response; Remission; Functioning; Relapse; 2-year follow-up;
D O I
暂无
中图分类号
学科分类号
摘要
Aim of the study was to examine the course of schizophrenia patients within 2 years after discharge. Within a multicenter study of the German Competence Network on Schizophrenia, patients suffering from a schizophrenia spectrum disorder were examined regarding their psychopathological improvement, tolerability, and the treatment regime applied during hospitalization and a 2-year follow-up period. Response, remission, the level of everyday functioning, and relapse were furthermore evaluated during the follow-up period using established definitions for these outcome domains. The psychopharmacological treatment was specifically evaluated in terms of a potential association with relapse. 149 patients were available for analysis, with 65% of the patients being in response, 52% in symptomatic remission, and 64% having a satisfiable everyday functioning 2 years after their discharge from hospital. Despite these favorable outcome rates, 63% of the patients suffered from a relapse within the 2-year follow-up period with 86% of these patients being rehospitalized. Discharge non-responder and non-remitter were twice as likely to relapse during follow-up. A significant decrease of side-effects was observed with negligible rates of extrapyramidal side-effects, sedation, and weight gain during follow-up. Patients receiving treatment with atypical antipsychotics were found to have the lowest risk to relapse (p < 0.0001). The results highlight the natural and unsteady course of schizophrenia in most patients underlining the need to develop more specific treatment strategies ensuring ongoing stability and preventing relapse.
引用
收藏
页码:661 / 671
页数:10
相关论文
共 50 条
  • [21] Patients with PTSD after intensive care avoid hospital contact at 2-year follow-up
    Capuzzo, M.
    Bertacchini, S.
    Jones, C.
    Griffiths, R.
    Ambrosio, M. R.
    Bondanelli, M.
    Alvisi, R.
    ACTA ANAESTHESIOLOGICA SCANDINAVICA, 2008, 52 (02) : 313 - 314
  • [22] Anti-CD20 immunotherapy in progressive multiple sclerosis: 2-year real-world follow-up of 108 patients
    Einsiedler, Maximilian
    Kremer, Laurent
    Fleury, Marie
    Collongues, Nicolas
    De Seze, Jerome
    Bigaut, Kevin
    JOURNAL OF NEUROLOGY, 2022, 269 (09) : 4846 - 4852
  • [23] Anti-CD20 immunotherapy in progressive multiple sclerosis: 2-year real-world follow-up of 108 patients
    Maximilian Einsiedler
    Laurent Kremer
    Marie Fleury
    Nicolas Collongues
    Jérôme De Sèze
    Kévin Bigaut
    Journal of Neurology, 2022, 269 : 4846 - 4852
  • [24] TRACHOMA VACCINE FIELD TRIAL IN INDIA - RESULTS OF 2-YEAR FOLLOW-UP
    DHIR, SP
    AGARWAL, LP
    GUPTA, SB
    DETELS, R
    WANG, SP
    GRAYSTON, JT
    INDIAN JOURNAL OF MEDICAL RESEARCH, 1968, 56 (08) : 1289 - &
  • [25] Long-term outcome of switching from clozapine to zotepine in refractory schizophrenia: a 2-year follow-up study
    Lin, CC
    Chen, JY
    Bai, YM
    Wang, YC
    Liou, YJ
    Lin, WK
    Chen, TT
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2005, 15 : S500 - S501
  • [26] Predictors of Cladribine Effectiveness and Safety in Multiple Sclerosis: A Real-World, Multicenter, 2-Year Follow-Up Study
    Maria Petracca
    Serena Ruggieri
    Elena Barbuti
    Antonio Ianniello
    Roberta Fantozzi
    Giorgia Teresa Maniscalco
    Vincenzo Andreone
    Doriana Landi
    Girolama Alessandra Marfia
    Maria Di Gregorio
    Rosa Iodice
    Leonardo Sinisi
    Elisabetta Maida
    Rosanna Missione
    Cinzia Coppola
    Simona Bonavita
    Giovanna Borriello
    Diego Centonze
    Giacomo Lus
    Carlo Pozzilli
    Elisabetta Signoriello
    Neurology and Therapy, 2022, 11 : 1193 - 1208
  • [27] Predictors of Cladribine Effectiveness and Safety in Multiple Sclerosis: A Real-World, Multicenter, 2-Year Follow-Up Study
    Petracca, Maria
    Ruggieri, Serena
    Barbuti, Elena
    Ianniello, Antonio
    Fantozzi, Roberta
    Maniscalco, Giorgia Teresa
    Andreone, Vincenzo
    Landi, Doriana
    Marfia, Girolama Alessandra
    Di Gregorio, Maria
    Iodice, Rosa
    Sinisi, Leonardo
    Maida, Elisabetta
    Missione, Rosanna
    Coppola, Cinzia
    Bonavita, Simona
    Borriello, Giovanna
    Centonze, Diego
    Lus, Giacomo
    Pozzilli, Carlo
    Signoriello, Elisabetta
    NEUROLOGY AND THERAPY, 2022, 11 (03) : 1193 - 1208
  • [28] TREATMENT OF THROMBOANGIITIS OBLITERANS 2-YEAR FOLLOW-UP AFTER SYMPATHECTOMY
    MESSINGER, WJ
    GOODMAN, EN
    WHITE, JC
    AMERICAN JOURNAL OF MEDICINE, 1949, 6 (02): : 168 - 176
  • [29] Follow-up report on the 2-year cardiac data from a deferasirox monotherapy trial
    Wood, John C.
    Glynos, Tara
    Thompson, Alexis
    Giardina, Patricia
    Harmatz, Paul
    Kang, Barinder P.
    Paley, Carole
    Coates, Thomas D.
    AMERICAN JOURNAL OF HEMATOLOGY, 2010, 85 (10) : 818 - 819
  • [30] INFLIXIMAB, ADALIMUMAB AND ETANERCEPT, A FIVE-YEAR FOLLOW-UP FROM A REAL-WORLD COHORT
    Valencia, Omaira
    Santos, Pedro
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2019, 25 : S59 - S59